FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer
| Autor: | Cathy Eng, Caly Chien, James C. Yao, Takayuki Yoshino, Zhao Yang, Josep Tabernero, Alberto Sobrero, William Schelman, Marek K. Kania, Arvind Dasari |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Dasari A, Yao J] Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA. [Sobrero A] Ospedale Policlinico San Martino – IRCCS, Largo R. Benzi n.10, Ospedale Policlinico San Martino, Padiglione ex Microbiologia, Piano Terra Levante, 16132, Genova, Italy. [Yoshino T] Department of Gastroenterology & Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 270-8577, Japan. [Schelman W] Clinical Development, Hutchison MediPharma International Incorporated, 25A Vreeland Road, Suite 304, Florham Park, NJ 07932, USA. [Yang Z] Biostatistics, Hutchison MediPharma International Incorporated, 25A Vreeland Road, Suite 304, Florham Park, NJ 07932, USA. [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.drug_class Colorectal cancer medicine.medical_treatment VEGF receptors Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] Angiogenesis Inhibitors Antineoplastic Agents Placebo Other subheadings::Other subheadings::/drug therapy [Other subheadings] Tyrosine-kinase inhibitor 03 medical and health sciences chemistry.chemical_compound Còlon - Càncer - Tractament 0302 clinical medicine Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [DISEASES] Refractory Double-Blind Method Internal medicine Regorafenib Recte - Càncer - Tractament medicine Humans 030212 general & internal medicine Protein Kinase Inhibitors Benzofurans Chemotherapy biology business.industry Fruquintinib acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS] diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] General Medicine medicine.disease Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales [ENFERMEDADES] chemistry 030220 oncology & carcinogenesis biology.protein Avaluació de resultats (Assistència sanitària) Quinazolines Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS] business Colorectal Neoplasms |
| Zdroj: | Scientia |
| ISSN: | 1744-8301 |
| Popis: | Fruquintinib, a novel, highly selective, small-molecule tyrosine kinase inhibitor of VEGF receptors (VEGFRs)-1, -2 and -3, is approved in China for the treatment of metastatic colorectal cancer. FRESCO-2, a global, randomized, double-blind, placebo-controlled, Phase III study, is investigating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer. Key inclusion criteria include: progression on or intolerance to TAS-102 and/or regorafenib; and prior treatment with approved chemotherapy, anti-VEGF therapy, and, ifLay abstract Fruquintinib is a drug that slows down, reduces or prevents the growth of vessels that supply blood to certain tumors. Fruquintinib is approved in China for the treatment of cancer of the colon and rectum that has spread to these parts of the body from the primary site of cancer: metastatic colorectal cancer. The FRESCO-2 study is being conducted globally to determine how safe and effective fruquintinib is at treating patients with metastatic colorectal cancer that has grown or spread following other forms of treatment, such as chemotherapy. About 687 patients will be enrolled globally to receive either fruquintinib or a matching placebo in a 2:1 ratio, respectively. The FRESCO-2 study is enrolling patients in the USA, Europe, Australia and Japan. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|